<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001657'>Long QT syndrome</z:hpo> is characterized by electrocardiographic appearance of long QT intervals and propensity to polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Aggressive anticipatory clinical management is required for a good outcome, especially in the symptomatic neonate </plain></SENT>
<SENT sid="2" pm="."><plain>We present a neonate with a compound mutation with refractory <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> that necessitated multimodal pharmacotherapy with <z:chebi fb="0" ids="6456">lidocaine</z:chebi>, esmolol, and <z:chebi fb="0" ids="2663">amiodarone</z:chebi> along with ventricular pacing </plain></SENT>
<SENT sid="3" pm="."><plain>Despite <z:mpath ids='MPATH_458'>normal</z:mpath> serum <z:chebi fb="0" ids="6456">lidocaine</z:chebi> levels, complex pharmacokinetic interactions resulted in presumed neurotoxicity due to <z:chebi fb="0" ids="6456">lidocaine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>This report discusses the implications and challenges of management of a neonate with compound long mutations </plain></SENT>
</text></document>